PRQR Relative Valuation
PRQR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRQR is overvalued; if below, it's undervalued.
Historical Valuation
ProQR Therapeutics NV (PRQR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.14. The fair price of ProQR Therapeutics NV (PRQR) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.08
Fair
-3.91
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
ProQR Therapeutics NV. (PRQR) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.79. The thresholds are as follows: Strongly Undervalued below -6.36, Undervalued between -6.36 and -4.08, Fairly Valued between 0.49 and -4.08, Overvalued between 0.49 and 2.78, and Strongly Overvalued above 2.78. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.79
EV/EBIT
ProQR Therapeutics NV. (PRQR) has a current EV/EBIT of -1.79. The 5-year average EV/EBIT is -2.77. The thresholds are as follows: Strongly Undervalued below -8.89, Undervalued between -8.89 and -5.83, Fairly Valued between 0.29 and -5.83, Overvalued between 0.29 and 3.34, and Strongly Overvalued above 3.34. The current Forward EV/EBIT of -1.79 falls within the Historic Trend Line -Fairly Valued range.
9.86
PS
ProQR Therapeutics NV. (PRQR) has a current PS of 9.86. The 5-year average PS is 78.44. The thresholds are as follows: Strongly Undervalued below -258.18, Undervalued between -258.18 and -89.87, Fairly Valued between 246.75 and -89.87, Overvalued between 246.75 and 415.06, and Strongly Overvalued above 415.06. The current Forward PS of 9.86 falls within the Historic Trend Line -Fairly Valued range.
-3.37
P/OCF
ProQR Therapeutics NV. (PRQR) has a current P/OCF of -3.37. The 5-year average P/OCF is -4.60. The thresholds are as follows: Strongly Undervalued below -13.28, Undervalued between -13.28 and -8.94, Fairly Valued between -0.26 and -8.94, Overvalued between -0.26 and 4.08, and Strongly Overvalued above 4.08. The current Forward P/OCF of -3.37 falls within the Historic Trend Line -Fairly Valued range.
-2.99
P/FCF
ProQR Therapeutics NV. (PRQR) has a current P/FCF of -2.99. The 5-year average P/FCF is -7.05. The thresholds are as follows: Strongly Undervalued below -17.52, Undervalued between -17.52 and -12.29, Fairly Valued between -1.81 and -12.29, Overvalued between -1.81 and 3.42, and Strongly Overvalued above 3.42. The current Forward P/FCF of -2.99 falls within the Historic Trend Line -Fairly Valued range.
ProQR Therapeutics NV (PRQR) has a current Price-to-Book (P/B) ratio of 3.18. Compared to its 3-year average P/B ratio of 3.84 , the current P/B ratio is approximately -17.13% higher. Relative to its 5-year average P/B ratio of 3.33, the current P/B ratio is about -4.41% higher. ProQR Therapeutics NV (PRQR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -14.58%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -22.97% , the current FCF yield is about -100.00% lower.
3.36
P/B
Median3y
3.84
Median5y
3.33
-27.22
FCF Yield
Median3y
-14.58
Median5y
-22.97
Competitors Valuation Multiple
The average P/S ratio for PRQR's competitors is 0.00, providing a benchmark for relative valuation. ProQR Therapeutics NV Corp (PRQR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -26.78%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PRQR decreased by 20.00% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -203.67 to -377.56.
The secondary factor is the Revenue Growth, contributed -26.78%to the performance.
Overall, the performance of PRQR in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is ProQR Therapeutics NV (PRQR) currently overvalued or undervalued?
What is ProQR Therapeutics NV (PRQR) fair value?
How does PRQR's valuation metrics compare to the industry average?
What is the current P/B ratio for ProQR Therapeutics NV (PRQR) as of Dec 05 2025?
What is the current FCF Yield for ProQR Therapeutics NV (PRQR) as of Dec 05 2025?
What is the current Forward P/E ratio for ProQR Therapeutics NV (PRQR) as of Dec 05 2025?